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The diagnosis and treatment of acute myeloid leukemia
(AML) has been a challenge for clinicians because of
multiple pathogenic origins, especially genetic mutations
which can influence its diagnosis, prognosis and
treatment outcomes. In the last 10 - 15 years, several
novel genetic markers were introduced for AML to
support its diagnosis, prognostication and monitoring of
treatment efficacy. These makers are categorized into
favourable and unfavourable, based on disease outcome,
and are used for predicting disease progression at the
time of diagnosis as well as response to chemotherapy.1
In current practice, molecular detection of MRD by PCR
is the most specific and sensitive method. Molecular
identification of MRD has increased the disease
progression-free survival and overall survival of AML
patients by predicting the relapse of disease, thus
providing opportunity to the clinician to re-examine
patients during their clinical and hematological remission
period prior to overt hematological relapse. Treatment of
MRD has a greater probability of success, is less
distressing for the patients, and also has a lower cost
than the treatment of an overt hematological relapse.2
Wilm's tumor (WT1) gene expression appears to be a
highly promising molecular marker for MRD in leukemic
patients, particularly in AML. WT1 gene is located on
chromosome 11p13 and encodes a zinc finger
transcription factor. It is implicated in cell proliferation
and differentiation. WT1 is known to inhibit apoptosis via
TP53 and BCL2. In many leukemic patients at the time
of diagnosis, WT1 is highly expressed and it plays a
significant role in leukomogenesis.3
WT1 expression is markedly low in cells of normal
healthy individuals, with the exception of the CD 34+
hematopoietic progenitors. The expression of WT1 gene
in leukemic cell is much higher than in normal bone
marrow or peripheral cells. Consequently, this gene is
suitable as a marker for monitoring MRD in AML either in
bone marrow or peripheral blood samples, particularly in
patients with normal cytogenetics or without specific
marker identified.4 Several studies have documented
promising role of WT1 as an indicator of treatment
outcome in AML.5 However, literature review revealed
scarcity of data, addressing the role of this important
marker in Pakistani AML patients.
In a pilot study, the authors quantified WT1 levels by RT
PCR in 5 male patients with AML. All patients had
normal karyotype and their mean age was 32 years
(16 - 45). According to FAB classification, 2 patients
were diagnosed as AML-M1, whereas 3 had AML-M2. All
patients were in different phases of treatment at the time
of analysis; 2 treatment naïve, 2 completed their
induction phase, and 1 had completed consolidation
phase. For WT1 expression analysis, 5 mL of whole
blood was collected in an EDTA containing tube from
each participant. The samples were transferred
immediately to the laboratory for processing and
preservation of nucleic acid (RNA) at -8°C.
For WT1 analysis, complementary DNA (cDNA) was
synthesized from RNA extracted from patient samples.
This cDNA was utilized for amplification by real time
PCR using primers specific for WT1 gene. Standards
and controls were run in parallel for ensuring quality
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ABSTRACT
Currently, there is an effort to predict relapse by follow-up monitoring of MRD and subsequently to begin the treatment of
the patients during their clinical and hematological remission prior to overt hematological relapse. Expression of WT1 in
AML is known to be independently associated with significant inferior response to therapy and short survival outcome.
Follow-up monitoring of WT1 gene expression during or after therapy would be a valuable predictive marker for early
recurrence or relapse of AML disease. This pilot study evaluated newly diagnosed and post-induction or consolidation
chemotherapy of AML patients who were registered with the Oncology Clinics of the Aga Khan University Hospital,
Karachi. High WT1 burden (> 5000 copies/ml) in 2 patients was indicative of early recurrence of the disease along with
shorter disease-free and overall survival. Low WT1 expression (< 200 copies/ml) in 2 patients after induction and
consolidation therapy, respectively, was suggestive of better prognosis.
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assurance. WT1 gene expression was quantified using a
validated standard curve, normalized with ABL (internal
control) copy number and ratio of WT1 copies/ABL
copies. WT1 levels were expressed as copies/mL of
blood and also as ratio of WT1/ABL. The standard
curves were generated by serial dilution of plasmid DNA
containing insert of WT1 gene. For the assessment of
quality parameters, positive and negative controls were
included in every batch of assay.
Relatively higher level of WT1 mRNA (4000 - 9500
copies/ml) was detected in treatment naïve patients,
whereas only 100 - 250 copies/ml were seen in 2
patients (one was receiving induction and the other
patient was on consolidation therapy). In addition, one
patient who received induction therapy showed raised
WT1 mRNA levels (7700 copies /ml).
WTI expression correlates with disease status both at
the time of diagnosis and then different phases of the
treatment. More than 5000 copies of WTI/ml were
detected in one treatment naïve and in one patient after
induction chemotherapy. High WT1 burden in both these
patients is indicative of early recurrence of the disease
along with shorter disease-free and overall survival. The
low WT1 expression (< 200 copies/ml) in 2 patients after
induction and consolidation therapy respectively was
suggestive of better prognosis.
The significant copy number determent is yet to be
established, however, a copy number of less than 200 is
classified as lower level detection of MRD. The
significance of WT1 in disease monitoring is well proven.
However, absolute significant values are yet to be
established as larger studies are required to establish
accurate cut-off values to label MRD. Nevertheless,
correlation of baseline values with follow-up levels
provides significant insight in prognosis of the condition.6
This is confirmed in various studies that WTI is a good
prognostic indicator in 80% of AML for disease
monitoring and represented as name of “panleukemic
marker”. Since WT1 expression reflects the burden of
more immature leukemic cells, it offers the advantage of
easier and more stringent evaluation over time.6 In WHO
2008 AML classification FLT3-ITD, CEBPA, NPM1,
RUNX1-RUNXT1 (translocation 8; 21) and core binding
factor with (inversion and translocation of 16;16) are
already established for prognostication. However, all
these markers are tested only at the time of initial
diagnosis. WT1 has an additional advantage of being
utilized as an indicator of MRD. Therefore, baseline
assessment along with follow-up levels provides better
assessment of the disease behavior.
To date, majority of the studies published for the role of
WT1 as an indicator of treatment outcome was
conducted in Western countries; whereas, few studies
from India, Iran and Middle Eastern countries are also
available. To the best of the authors' knowledge, current
study is the first one to be reported from Pakistan. Since,
the sample size is small, biological difference of the
disease in Pakistani population cannot be commented.
Larger studies are required in this regard to address the
variation in Pakistani population.
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